The role of calpains in myocardial remodelling and heart failure

Cardiovascular Research

Volumn 96, Issue 1, 2012, Pages 38-45

  Letavernier, Emmanuel ^a   Zafrani, Lara ^a   Perez, Joëlle ^a   Letavernier, Béatrice ^a   Haymann, Jean Philippe ^a   Baud, Laurent ^a  

^a INSERM   (France)

Author keywords

Calpains; Extracellular matrix; Heart failure; Myocardial remodelling

Indexed keywords

[1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; ABC TRANSPORTER A1; CALPAIN; CALPAIN 1; CALPAIN 2; CALPAIN 3; CALPASTATIN; CHROMOGRANIN B; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GELATINASE B; HEAT SHOCK PROTEIN 10; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOLIPASE C; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CELL DEATH; CELL REGENERATION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIABETOGENESIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SARCOLEMMA; SARCOMERE;

ANIMALS; APOPTOSIS; CALPAIN; CARDIOMEGALY; FIBROSIS; HEART FAILURE; HUMANS; INFLAMMATION; NECROSIS; TRANSCRIPTION FACTORS; VENTRICULAR REMODELING;

EID: 84866660710     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs099     Document Type: Review

References (64)

1. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008;358:1370-1380.
2. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011;378:704-712.
3. Nabeebaccus A, Zhang M, Shah AM. NADPH oxidases and cardiac remodelling. Heart Fail Rev 2011;16:5-12.
4. Müller AL, Dhalla NS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 2011. Jul 8. [Epub ahead of print]
5. Goll DE, Thompson VF, Li H,WeiW, Cong J. The calpain system. Physiol Rev 2003;83: 731-801.
6. Zatz M, Starling A. Calpains and disease. N Engl J Med 2005;352:2413-2423.
7. Fougerousse F, Anderson LV, Delezoide AL, Suel L, Durand M, Beckmann JS. Calpain3 expression during human cardiogenesis. Neuromuscul Disord 2000;10:251-256.
8. Inserte J, Barba I, Hernando V, Garcia-Dorado D. Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. Cardiovasc Res 2009;81:116-122.
9. Shumway SD, Maki M, Miyamoto S. The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. J Biol Chem 1999;274: 30874-30881.
10. Wang N, Chen W, Linsel-Nitschke P, Martinez LO, Agerholm-Larsen B, Silver DL et al. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003;111:99-107.
11. Tompa P, Buzder-Lantos P, Tantos A, Farkas A, Szilágyi A, Bánó czi Z et al. On the sequential determinants of calpain cleavage. J Biol Chem 2004;279:20775-20785.
12. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010;85:413-423.
13. Azam M, Andrabi SS, Sahr KE, Kamath L, Kuliopulos A, Chishti AH. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol 2001;21:2213-2220.
14. Dutt P, Croall DE, Arthur JS, Veyra TD, Williams K, Elce JS et al. m-Calpain is required for preimplantation embryonic development in mice. BMC Dev Biol 2006;6:3.
15. Arthur JS, Elce JS, Hegadorn C, Williams K, Greer PA. Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol Cell Biol 2000;20:4474-4481.
16. Mellgren RL, Zhang W, Miyake K, McNeil PL. Calpain is required for the rapid, calcium-dependent repair of wounded plasma membrane. J Biol Chem 2007;282: 2567-2575.
17. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG et al. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res 2007;100:1071-1078.
18. Deshpande RV, Goust JM, Chakrabarti AK, Barbosa E, Hogan EL, Banik NL. Calpain expression in lymphoid cells. Increased mRNA and protein levels after cell activation. J Biol Chem 1995;270:2497-2505.
19. Fushimi K, Nakashima S, Banno Y, Akaike A, Takigawa M, Shimizu K. Implication of prostaglandin E(2) in TNF-alpha-induced release of m-calpain from HCS-2/8 chondrocytes. Inhibition of m-calpain release by NSAIDs. Osteoarthr Cartilage 2004;12: 895-903.
20. Letavernier B, Zafrani L, Nassar D, Perez1 J, Levi C, Bellocq A et al. Calpains contribute to vascular repair in rapidly progressive form of glomerulonephritis: potential role of their externalization. Arterioscler Thromb Vasc Biol 2012;32:335-342.
21. Hood JL, Brooks WH, Roszman TL. Subcellular mobility of the calpain/calpastatin network: an organelle transient. Bioessays 2006;28:850-859.
22. Kifor O, Kifor I, Moore FD Jr, Butters RR Jr, Brown EM. m-Calpain colocalizes with the calcium-sensing receptor (CaR) in caveolae in parathyroid cells and participates in degradation of the CaR. J Biol Chem 2003;278:31167-31176.
23. Xu L, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone induces phosphorylation of mu-and m-calpain in association with increased secretion, cell migration, and invasion. J Biol Chem 2004;279: 53683-53690.
24. Xu L, Deng X. Protein kinase Ciota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of micro-and m-calpains. J Biol Chem 2006; 281:4457-4466.
25. Xu L, Deng X. Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu-and m-calpains. J Biol Chem 2006;281: 35567-35575.
26. Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, Polikov VS et al. Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 2010;133:808-821.
27. Radisky DC, Stallings-Mann M, Hirai Y, Bissell MJ. Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol 2009;10:228-234.
28. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600.
29. Patterson C, Portbury AL, Schisler JC, Willis MS. Tear me down: role of calpain in the development of cardiac ventricular hypertrophy. Circ Res 2011;109:453-462.
30. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P et al. Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111:2319-2325.
31. Letavernier E, Perez J, Bellocq A, Mesnard L, de Castro Keller A, Haymann JP et al. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 2008;102:720-728.
32. Heidrich FM, Zhang K, Estrada M, Huang Y, Giordano FJ, Ehrlich BE. Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes. Circ Res 2008;102:1230-1238.
33. Heidrich FM, Ehrlich BE. Calcium, calpains, and cardiac hypertrophy: a new link. Circ Res 2009;104:e19-20.
34. Heidrich FM, Zhang K, Strasser RH. Chromogranin B in calpain-mediated hypertrophic signaling-the chicken, the egg, or even both.? Circ Res 2011;109:e53.
35. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kB in the heart: to be or not to NF-kB. Circ Res 2011;108:1122-1132.
36. Burkard N, Becher J, Heindl C, Neyses L, Schuh K, Ritter O. Targeted proteolysis sustains calcineurin activation. Circulation 2005;111:1045-1053.
37. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurinmediated cardiac hypertrophic growth. Mol Cell Biol 2002;22:7603-7613.
38. Hingtgen SD, Li Z, Kutschke W, Tian X, Sharma RV, Davisson RL. Superoxide scavenging and Akt inhibition in myocardium ameliorate pressure overload-induced NF-kB activation and cardiac hypertrophy. Physiol Genomics 2010;41:127-136.
39. Beltran L, Chaussade C, Vanhaesebroeck B, Cutillas PR. Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. Proc Natl Acad Sci USA 2011;108:16217-16222.
40. Valen G. Innate immunity and remodelling. Heart Fail Rev 2011;16:71-78.
41. Fildes JE, Shaw SM, Yonan N, Williams SG. The immune system and chronic heart failure: is the heart in control? J Am Coll Cardiol 2009;53:1013-1020.
42. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009;81:474-481.
43. Scalia R, Gong Y, Berzins B, Freund B, Feather D, Landesberg G et al. A novel role for calpain in the endothelial dysfunction induced by activation of angiotensin II type 1 receptor signaling. Circ Res 2011;108:1102-1111.
44. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011;89:265-272.
45. Abe M, Oda N, Sato Y. Cell-associated activation of latent transforming growth factor-beta by calpain. J Cell Physiol 1998;174:186-193.
46. Gressner OA, Lahme B, Siluschek M, Rehbein K, Herrmann J, Weiskirchen R et al. Activation of TGF-beta within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J Cell Mol Med 2008;12:2717-2730.
47. Ma W, Han W, Greer PA, Tuder RM, Toque HA, Wang KK et al. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest 2011;121: 4548-4566.
48. Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Agulló L, Cabestrero A. The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion. Cardiovasc Res 2006;70:274-285.
49. Portbury AL, Willis MS, Patterson C. Tearin' up my heart: proteolysis in the cardiac sarcomere. J Biol Chem 2011;286:9929-9934.
50. Taneike M, Mizote I, Morita T,Watanabe T, Hikoso S, Yamaguchi O et al. Calpain protects the heart from hemodynamic stress. J Biol Chem 2011;286:32170-32177.
51. Spaeth CS, Boydston EA, Figard LR, Zuzek A, Bittner GD. A model for sealing plasmalemmal damage in neurons and other eukaryotic cells. J Neurosci 2010;30: 15790-15800.
52. Mellgren RL, Huang X. Fetuin A stabilizes m-calpain and facilitates plasma membrane repair. J Biol Chem 2007;282:35868-35877.
53. Averna M, De Tullio R, Salamino F, Minafra R, Pontremoli S, Melloni E. Age-dependent degradation of calpastatin in kidney of hypertensive rats. J Biol Chem 2001;276: 38426-38432.
54. Li Y, Ma J, Zhu H, Singh M, Hill D, Greer PA et al. Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 2011;60:2985-2994.
55. Stalker TJ, Gong Y, Scalia R. The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes 2005;54:1132-1140.
56. Miyazaki T, Taketomi Y, Takimoto M, Lei XF, Arita S, Kim-Kaneyama JR et al. m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. Circulation 2011; 124:2522-2532.
57. Subramanian V, Uchida HA, Ijaz T, Moorleghen JJ, Howatt DA, Balakrishnan A. Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in LDL receptor deficient mice. J Cardiovasc Pharmacol 2012;59:66-76.
58. Sandmann S, Yu M, Unger T. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction-effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor. Br J Pharmacol 2001;132:767-777.
59. Mani SK, Balasubramanian S, Zavadzkas JA, Jeffords LB, Rivers WT, Zile MR et al. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol 2009;297:H1744-H1751.
60. Bukowska A, Lendeckel U, Bode-Böger SM, Goette A. Physiologic and pathophysiologic role of calpain: implications for the occurrence of atrial fibrillation. Cardiovasc Ther 2010; Nov 25. [Epub ahead of print].
61. Yang D, Ma S, Tan Y, Li D, Tang B, Zhang X et al. Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. Int J Mol Med 2010;26:159-164.
62. Razeghi P, Volpini KC, Wang ME, Youker KA, Stepkowski S, Taegtmeyer H. Mechanical unloading of the heart activates the calpain system. J Mol Cell Cardiol 2007;42: 449-452.
63. Hernando V, Inserte J, Sartó rio CL, Parra VM, Poncelas-Nozal M, Garcia-Dorado D. Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. J Mol Cell Cardiol 2010;49:271-279.
64. Li X, Li Y, Shan L, Shen E, Chen R, Peng T. Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. Cardiovasc Res 2009;83:72-79.